162939-176

Utility of liquid biopsies to assess circulating tumor DNA in patients with lung adenocarcinoma.

Subcategory: 
Category: 
Tumor Biology
Session Type and Session Title: 
This abstract will not be presented at the 2016 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract Number: 

e23097

Citation: 
J Clin Oncol 34, 2016 (suppl; abstr e23097)
Author(s): 
Maria Clemence Schwaederle, Sandip Pravin Patel, Hatim Husain, Megumi Ikeda, Richard Burnham Lanman, Kimberly C. Banks, AmirAli Talasaz, Lyudmila Bazhenova, Razelle Kurzrock; Center for Personalized Cancer Therapy, UCSD Moores Cancer Center, La Jolla, CA; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UCSD Moores Cancer Center, La Jolla, CA; Guardant Health, Inc., Redwood City, CA; University of California, San Diego, La Jolla, CA

Abstract Disclosures

Abstract: 

Background: Liquid biopsies were used to assess genomic alterations in plasma circulating tumor DNA (ctDNA) from patients with non-small cell lung adenocarcinoma (NSCLC), and therapeutic outcomes analyzed. Methods: ctDNA testing (digital next-generation sequencing (NGS)) was performed in 88 patients with advanced NSCLC; (54 or 68 gene panel; 40 and 48 patients, respectively (Guardant Health, Inc. (Guardant360 test))) (Clinical Laboratory Improvement Amendment (CLIA) laboratory). Fifty-five patients (62.5%) also had some tissue molecular testing, 37 of whom had a consistent tissue NGS panel ( ≥ 182-genes). Results: Eighty-two percent of patients (72/88) had ≥ 1 ctDNA alteration(s) (median = 2 alterations), most frequently TP53 (44.3% of patients), EGFR (27.3%), MET (14.8%), KRAS (13.6%), and ALK (6.8%). Retrospective analysis showed that 25 of 88 patients (28.4%) had received a therapy matching at least one ctDNA alteration(s) (most frequently an inhibitor of EGFR (N = 18), ALK, BRAF, other). Sixty-five percent of evaluable (N = 5 patients, too early) matched patients (N = 13/20) achieved stable disease (SD) ≥ 6 months or partial response (PR). The median progression-free survival for the 25 matched patients was 13.9 months. For the 37 patients who had both the tissue NGS panel and the ctDNA test (median 1.3 months (range, 0.1 to 20.9) between tissue biopsy and blood draw), the concordance rate for EGFR ctDNA alterations with tissue NGS was 70.3% (k = 0.361), with higher concordance when time interval between tissue and blood tests was ≤ 1.3 months. When we only considered patients in whom ctDNA confirmed present (N = 27), the EGFR concordance was 77.8% (k = 0.526). Fifty-one patients (58%) did not have the tissue NGS test performed, including 33 (37.5%) who had no other tissue molecular testing, usually because of inadequate tissue or potential morbidity for repeat biopsy. Conclusions: ctDNA frequently revealed genomic alterations in NSCLC adenocarcinoma, including in difficult-to-biopsy patients. Patients who received cognate therapies demonstrated a high rate of SD ≥ 6months/PR, suggesting clinical utility.